Results 131 to 140 of about 107,308 (356)

A Cell-Adapted Live-Attenuated Vaccine Protects Pigs against the Contemporary Pandemic African Swine Fever Virus

open access: green, 2023
Quang Lam Truong   +17 more
openalex   +2 more sources

Digital Point‐of‐Care Testing Device Based on Bioluminescent Pyrophosphate in Real‐Time and Recombinase‐aid Amplification

open access: yesAdvanced Intelligent Systems, EarlyView.
A point‐of‐care testing method based on solvent‐responsive magnetic beads suitable for large‐area diagnosis and mutation screening in remote areas was developed to detect it by combining bioluminescenct pyrophosphate in real‐time technology and recombinase‐aid amplification technology.
Zhongjie Fei   +8 more
wiley   +1 more source

Cost-effectiveness analysis of intranasal live attenuated vaccine (LAIV) versus injectable inactivated influenza vaccine (TIV) for Canadian children and adolescents

open access: yesClinicoEconomics and Outcomes Research, 2012
Jean-Eric Tarride,1,2 Natasha Burke,1,2 Camilla Von Keyserlingk,1,2 Daria O'Reilly,1,2 Feng Xie,1,2 Ron Goeree1,21Programs for Assessment of Technology in Health (PATH) Research Institute, St Joseph's Healthcare Hamilton, Hamilton ...
Tarride JE   +5 more
doaj  

Tuberculosis vaccine strain _Mycobacterium bovis_ BCG Russia is a natural _recA_ mutant [PDF]

open access: yes, 2008
The current tuberculosis vaccine is a live vaccine derived from _Mycobacterium bovis_ and attenuated by serial _in vitro_ passaging. All vaccine substrains in use stem from one source, strain Bacille Calmette-Guérin.
Erik C. Boettger   +2 more
core   +1 more source

Uptake and impact of a new live attenuated influenza vaccine programme in England: early results of a pilot in primary school-age children, 2013/14 influenza season [PDF]

open access: diamond, 2014
Richard Pebody   +15 more
openalex   +1 more source

Cold-adapted, live attenuated influenza vaccine

open access: yesExpert Review of Vaccines, 2004
The recently licensed cold-adapted, live attenuated influenza vaccine (CAIV-T, FluMist, MedImmune Vaccines Inc.) has the potential to enhance control of epidemic influenza. The intranasal vaccine has proven safety and efficacy. Regulatory constraints and cost of CAIV-T have hampered the introduction of the vaccine in the first year. Unwarranted concern
openaire   +2 more sources

Establishment of a biosafe murine model of skeletal tuberculosis using Mycobacterium smegmatis

open access: yesAnimal Models and Experimental Medicine, EarlyView.
This study developed a biosafe, accessible, and versatile murine model of bone TB using Mycobacterium smegmatis, a fast‐growing, nonpathogenic mycobacterial species with high genomic homology to Mycobacterium tuberculosis. Three infection routes—subperiosteal calvarial injection, intratibial injection, and intracardiac (left ventricular) inoculation ...
Yewei Jia   +12 more
wiley   +1 more source

The use of live attenuated bacteria as a delivery system for heterologous antigens

open access: yes, 2004
Live attenuated mutants of several pathogenic bacteria have been exploited as potential vaccine vectors for heterologous antigen delivery by the mucosal route.
Brown, KA   +5 more
core   +1 more source

1183. Serum Bactericidal Activity Induced by Live Attenuated Pertussis Vaccine BPZE1 is Comparable to Boostrix™

open access: gold, 2021
Cheryl Keech   +4 more
openalex   +1 more source

Home - About - Disclaimer - Privacy